Top 10 Pharma Drug Discovery and Delivery Capital Raises in the U.S. – April 1st to 15th, 2025

Several interesting transactions closed in the Pharma Drug Discovery and Delivery sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.

PIPE

  1. Adaptin Bio, developer of biotechnology solutions focused on developing precision cancer therapies for the brain and other tissues, received approximately $7.7 million of development capital from investors on April 7, 2025 through a private placement.
  2. Serina Therapeutics, a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain, received $5 million of development capital from investors on April 8, 2025 through a private placement.

    Merger/Acquisition

    1. Anthos Therapeutics, operator of a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases, was acquired by Novartis for $3.1 billion on April 3, 2025.
    2. Intracellular Therapies, a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system, was acquired by Johnson & Johnson for approximately $15.02 billion on April 2, 2025.

    Later Stage VC

    1. Celestial Therapeutics, operator of a biopharmaceutical company focused on infectious diseases and inflammatory conditions, raised $550,000 of venture funding from investors on April 7, 2025.
    2. Neurona Therapeutics, developer of regenerative cell therapies designed for the treatment of chronic neurological disorders, raised $101.71 million of venture funding in a deal led by Cormorant Asset Management and Viking Global Investors on April 3, 2025, putting the company’s pre-money valuation at $495.29 million.

    Early Stage VC

    1. Pheast Therapeutics, provider of macrophage-targeted immunotherapies intended for cancer treatment, raised $76 million of Series A venture funding in a deal led by Catalio Capital Management and ARCH Venture Partners on April 10, 2025, putting the company’s pre-money valuation at $54 million.
    2. Synucure Therapeutics, operator of a biotechnology company intended to conduct research in brain degenerative disorders, raised $2.8 million of venture funding from Investissement Québec and other investors on April 7, 2025.

    Seed Round

    1. Auxilium, operator of a biotechnology research company intended to develop wound care technology, raised $1.5 million of pre-seed funding from investors on April 9, 2025.
    2. ImmuneBridge, developer of allogeneic cellular immunotherapies designed for advancing cancer treatment, raised $5.63 million through a combination of Seed II, Seed II-A and Seed II-B funding from investors on April 1, 2025, putting the company’s pre-money valuation at $5.37 million.

     

    #castleplacement #capitalraising #privateequity #venturecapital #investment #pharmaceuticals #biotechnology #pharmadrugdiscoveryanddelivery

    Diana Ruddy

    Managing Director

    Over 20 years of diverse experience in investment banking, consulting, and commercial lending. Developed transactions up to $350 million, sourcing debt and equity funding for domestic and international projects across a wide range of industries. Advised companies on expansion, mergers and acquisitions, financial structure, contract negotiation, and strategic planning. Industry experience includes healthcare, technology, energy, aviation, real estate, manufacturing, retail, agriculture, hospitality, financial services, and nonprofits. Bachelor of Science with highest honors in Finance from UMass Boston, and MBA with great distinction from Arizona State University W.P. Carey School of Business. FINRA Series 7, 66, 79 and 99 licenses.

    Diana Ruddy

    Diana Ruddy

    Managing Director

    Diana Ruddy

    Managing Director

    Please contact me if you have any questions or would like to discuss your capital raise:

    Email: Diana Ruddy druddy@castleplacement.com

    (C) (406) 868-3218

    Send us a message:

    Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement™ does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.

    CONTACT US

    Hi. We're not around right now. But you can send us an email and we'll get back to you, asap.

    Thanks, Ken

    Ken Margolis | Managing Partner Castle Placement, LLC
    1460 Broadway Street, Rte 400
    New York, New York 10036
    (212) 418-1188 | C: (516) 712-7784
    kmargolis@castleplacement.com

    Sending
    42513